Oppenheimer Downgrades GW Pharmaceuticals PLC- (NASDAQ:GWPH) to Market Perform

Oppenheimer cut shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) from an outperform rating to a market perform rating in a research report sent to investors on Wednesday, May 8th. They currently have $195.00 price target on the biopharmaceutical company’s stock.

GWPH has been the topic of a number of other research reports. BidaskClub cut GW Pharmaceuticals PLC- from a buy rating to a hold rating in a report on Thursday, February 21st. Morgan Stanley reissued a buy rating on shares of GW Pharmaceuticals PLC- in a research note on Tuesday, April 9th. Zacks Investment Research raised GW Pharmaceuticals PLC- from a hold rating to a buy rating and set a $193.00 price target on the stock in a research note on Thursday, April 11th. Cantor Fitzgerald reissued an overweight rating and set a $196.00 price target (up previously from $193.00) on shares of GW Pharmaceuticals PLC- in a research note on Monday, March 18th. Finally, CIBC raised GW Pharmaceuticals PLC- from a market perform rating to an outperform rating in a research note on Tuesday, May 7th. One equities research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. GW Pharmaceuticals PLC- presently has a consensus rating of Buy and a consensus price target of $205.40.

GWPH opened at $173.24 on Wednesday. The company has a market capitalization of $5.23 billion, a P/E ratio of -16.41 and a beta of 2.75. The company has a debt-to-equity ratio of 0.03, a quick ratio of 7.19 and a current ratio of 7.81. GW Pharmaceuticals PLC- has a 1-year low of $90.14 and a 1-year high of $196.00.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last released its quarterly earnings results on Monday, May 6th. The biopharmaceutical company reported ($1.68) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.48) by $0.80. The business had revenue of $39.20 million for the quarter, compared to analysts’ expectations of $12.32 million. GW Pharmaceuticals PLC- had a negative return on equity of 45.75% and a negative net margin of 458.79%. The company’s revenue was up 1189.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($3.12) EPS. As a group, equities research analysts forecast that GW Pharmaceuticals PLC- will post -4.76 earnings per share for the current fiscal year.

In related news, insider Adam D. George sold 258,324 shares of the stock in a transaction on Tuesday, May 7th. The stock was sold at an average price of $16.10, for a total value of $4,159,016.40. Following the completion of the sale, the insider now directly owns 268,324 shares in the company, valued at approximately $4,320,016.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Geoffrey W. Dr Guy sold 1,200,000 shares of the firm’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $14.69, for a total value of $17,628,000.00. Following the sale, the insider now owns 8,465,528 shares of the company’s stock, valued at $124,358,606.32. The disclosure for this sale can be found here. Over the last quarter, insiders sold 2,657,664 shares of company stock valued at $39,943,316. 5.50% of the stock is owned by insiders.

Large investors have recently bought and sold shares of the stock. Horan Capital Advisors LLC. bought a new position in GW Pharmaceuticals PLC- in the first quarter worth about $25,000. Exane Derivatives bought a new stake in shares of GW Pharmaceuticals PLC- during the first quarter valued at approximately $28,000. TCG Advisors LP bought a new stake in shares of GW Pharmaceuticals PLC- during the first quarter valued at approximately $29,000. Mckinley Capital Management LLC Delaware bought a new stake in shares of GW Pharmaceuticals PLC- during the fourth quarter valued at approximately $30,000. Finally, Institutional & Family Asset Management LLC bought a new stake in shares of GW Pharmaceuticals PLC- during the first quarter valued at approximately $31,000. Institutional investors and hedge funds own 79.07% of the company’s stock.

About GW Pharmaceuticals PLC-

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.

Featured Story: Stock Symbols Definition, Examples, Lookup

Analyst Recommendations for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.